Latest Breaking News On - Marvelon mercilon - Page 1 : comparemela.com

Organon Reports Results for the First Quarter Ended March 31, 2024

First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted.

United statesJersey cityNew jerseyCozaar hyzaarEli lillyAsia pacificKevin aliMarvelon mercilonWomen healthMerck co incOrganon coExchange commissionEuropean unionOther women healthChief executiveVolume based procurement

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Full year 2023 revenue of $6.3 billion, up 1% as-reported and 3% at constant currency Full year 2023 diluted earnings per share of $3.99 and non-GAAP Adjusted diluted earnings per share of.

New jerseyUnited statesJersey cityAsia pacificMarvelon mercilonCozaar hyzaarOrganon coMerck co incWomen healthOther women healthExchange commissionInterim operating modelSoutheast asiaVolume based procurementEjada systemEstablished brands

Organon Reports Results for the Third Quarter Ended September 30, 2023

Third quarter 2023 revenue of $1,519 million Third quarter 2023 diluted earnings per share of $0.23 and non-GAAP Adjusted diluted earnings per share of $0.87 Adjusted EBITDA of $447.

United statesJersey cityNew jerseyKevin aliMarvelon mercilonCozaar hyzaarAsia pacificExchange commissionMerck co incWomen healthOther women healthOrganon coEstablished brandsVolume based procurementOrganon investor relationsSecurities litigation reform act

Organon Reports Results for the Second Quarter Ended June 30, 2023

Organon Reports Results for the Second Quarter Ended June 30, 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesJersey cityAsia pacificCozaar hyzaarKevin aliCelestone soluspanCelestone chronodoseMarvelon mercilonAbbvie biotechnology ltdOrganon coWomen healthMerck co incExchange commissionOther women healthEstablished brands

Organon Reports Results for the First Quarter Ended March 31, 2023

First quarter 2023 revenue of $1,538 millionFirst quarter 2023 diluted earnings per share of $0.69 and non-GAAP Adjusted diluted earnings per share of $1.08Both reported and non-GAAP Adjusted diluted earnings per share include a negative impact of $0.03 per share for acquired in-process research and development (IPR.

New jerseyUnited statesJersey cityKevin aliCozaar hyzaarAlex arzenoCelestone chronodoseAsia pacificJennifer halchakMarvelon mercilonCelestone soluspanKate vossenWomen healthMerck co incOrganon coOther women health